Thrivent Financial for Lutherans Has $82.26 Million Stock Holdings in Enovis Co. (NYSE:ENOV)

Thrivent Financial for Lutherans reduced its stake in shares of Enovis Co. (NYSE:ENOV) by 0.3% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 1,819,873 shares of the company’s stock after selling 4,908 shares during the period. Thrivent Financial for Lutherans’ holdings in Enovis were worth $82,258,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in shares of Enovis by 19.9% in the first quarter. GAMMA Investing LLC now owns 1,085 shares of the company’s stock valued at $68,000 after purchasing an additional 180 shares in the last quarter. Treasurer of the State of North Carolina lifted its stake in Enovis by 1.0% in the 4th quarter. Treasurer of the State of North Carolina now owns 23,252 shares of the company’s stock valued at $1,303,000 after acquiring an additional 220 shares in the last quarter. Envestnet Portfolio Solutions Inc. boosted its position in Enovis by 5.4% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 5,185 shares of the company’s stock worth $290,000 after acquiring an additional 264 shares during the last quarter. State of Michigan Retirement System grew its stake in shares of Enovis by 2.5% during the 1st quarter. State of Michigan Retirement System now owns 12,202 shares of the company’s stock worth $762,000 after acquiring an additional 300 shares in the last quarter. Finally, Swiss National Bank raised its holdings in shares of Enovis by 0.3% in the first quarter. Swiss National Bank now owns 97,000 shares of the company’s stock valued at $6,058,000 after purchasing an additional 300 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on ENOV shares. JPMorgan Chase & Co. reduced their target price on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Evercore ISI cut their price target on shares of Enovis from $70.00 to $62.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Finally, Needham & Company LLC decreased their price objective on Enovis from $82.00 to $65.00 and set a “buy” rating for the company in a report on Thursday, August 8th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $69.13.

Enovis Stock Performance

Shares of ENOV stock opened at $43.67 on Friday. The company has a fifty day moving average price of $44.73 and a two-hundred day moving average price of $49.97. Enovis Co. has a one year low of $39.98 and a one year high of $65.03. The stock has a market cap of $2.40 billion, a P/E ratio of -29.11 and a beta of 1.92. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.26 and a quick ratio of 1.08.

Enovis (NYSE:ENOV) last issued its earnings results on Wednesday, August 7th. The company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.03. Enovis had a negative net margin of 4.73% and a positive return on equity of 4.06%. The company had revenue of $525.20 million for the quarter, compared to analysts’ expectations of $525.99 million. During the same period in the prior year, the firm earned $0.61 EPS. Enovis’s quarterly revenue was up 22.6% compared to the same quarter last year. As a group, equities analysts predict that Enovis Co. will post 2.7 EPS for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.